We have previously shown that MEKi treatment synergizes with IFN-γ to induce interferon-responsive MHC-I and PD-L1 expression in certain murine mammary cancer cell lines, but with only modest effects observed for MEKi treatment in the absence of IFN-γ[7]. This evidence concerns the gene IFNG and breast cancer.